Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block

NCT07153263 | Recruiting

• 1 other identifier: KY 20250819-10
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 2

Brief Summary

The aim of this clinical trial is to investigate the effects of local anesthetic diffusion range and sensory block range during retro-SCTLB(retro superior costotransverse ligament space block) and TPVB(thoracic paravertebral block) in patients undergoing CT-guided lung nodule localization. The main issue of the study is to determine the differences in the diffusion range and sensory block range of local anesthetics between the retro-SCTLB and TPVB nerve block methods.

Conditions

Pulmonary Nodules; Nerve Block

Keywords

nerve block; TPVB; ITPB; rSCTL

Outcome Measures

Primary Outcomes (1)

• Spread of local anesthetic into the paravertebral space

  Observation of incidence and thoracic level of local anesthetic spread into the paravertebral space with CT by a researcher who was blinded to group allocation

  15 minutes after completion of the nerve block

Secondary Outcomes (6)

• The range of the local anesthetic spreads to the intercostal space

  15 minutes after completion of the nerve block

• Observation of local anesthetic spread cephalocaudally in the erector spinae plane

  15 minutes after completion of the nerve block

• The range of the local anesthetic spread to the epidural space

  15 minutes after completion of the nerve block

• The range of the local anesthetic spread to the anterolateral vertebrae (sympathetic ganglion).

  15 minutes after completion of the nerve block

• Assessment of skin sensory block with ice

  15 minutes after completion of the nerve block

Study Arms (2)

retro-SCTLB group

EXPERIMENTAL

A total of 20 ml of the local anesthetic solution (0.375% ropivacaine 10ml+ iohexol 10ml) is injected in the retro-superior costotransverse ligament space in the retro-SCTLB group within 60 seconds.

Procedure: Ultrasound-guided retro-SCTLB

TPVB group

EXPERIMENTAL

A total of 20 ml of the local anesthetic solution (0.375% ropivacaine 10ml+ iohexol 10ml) is injected in the paravertebral space in the TPVB group within 60 seconds.

Procedure: Ultrasound-guided TPVB

Interventions

Ultrasound-guided retro-SCTLB PROCEDURE

Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the retro-SCTLB was performed under ultrasound guidance.

retro-SCTLB group

Ultrasound-guided TPVB PROCEDURE

Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the TPVB was performed under ultrasound guidance.

TPVB group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients scheduled for CT-guided lung nodule localization under local anesthesia will be selected
• aged 18-80 years
• BMI 18-30 kg/m²
• ASA classification I-III

You may not qualify if:

• Allergy to the study drug or local anesthetic;
• History of opioid abuse;
• Pre-existing skin infection at the puncture site of ITPN or TPVB;
• Peripheral infectious neuropathy;
• Dysfunction of blood coagulation

Sponsors & Collaborators

• Nanjing First Hospital, Nanjing Medical University: lead

Study Sites (2)

Tao Shan

Nanjing, Jiangsu, 210006, China

RECRUITING

Nanjing First Hospital

Nanjing, China

RECRUITING

MeSH Terms

Conditions

Multiple Pulmonary Nodules

Condition Hierarchy (Ancestors)

Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Tao Shan

  Nanjing First Hospital, Nanjing Medical University

  STUDY CHAIR

Central Study Contacts

Tao Shan

CONTACT

+8618852095135; shantao2021@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Attending physician

Study Record Dates

• First Submitted: August 21, 2025
• First Posted: September 3, 2025
• Study Start: September 12, 2025
• Primary Completion (Estimated): September 15, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: September 16, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)